A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

NCT03941873 PHASE1, PHASE2 COMPLETED Results posted

The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of sitravatinib as monotherapy and in combination with tislelizumab in participants with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) or gastric/gastroesophageal junction (G/GEJ) cancer.

Details

Lead sponsor	BeiGene
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	111
Start date	Thu Feb 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Mar 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Carcinoma, Hepatocellular
• Gastric/Gastroesophageal Junction Cancer

Interventions

• Sitravatinib
• Tislelizumab

Countries

China